Top Markets
#1 WYDE: End Hunger WYDE: End Hunger +2.71%
#2 MetaDAO MetaDAO +2.37%
#3 StonkBroker StonkBroker +2.30%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +2.27%
#5 PulseX PulseX +1.94%
#6 The Grays Currency The Grays Currency +1.93%
#7 Dual Dual +1.86%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +1.67%
#9 Fractal Bitcoin Fractal Bitcoin +1.59%
#10 Wrapped Pulse Wrapped Pulse +1.56%
Coin of the day
WYDE: End Hunger WYDE: End Hunger
Настройки
Язык
Pусский
Валюта
USD
Тема
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Ранг среди акций #20199
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Цена акции
$10.25
Последняя синхронизация: 2024-02-22
Рыночная капитализация
$137.83M
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
CN
Торговля Gracell Biotechnologies Inc. (GRCL)

Категория

Healthcare
История дивидендной доходности для Gracell Biotechnologies Inc. (GRCL)
Дивидендная доходность (TTM) компании Gracell Biotechnologies Inc. (тикер: GRCL) на 2026 составляет: 0
Средняя дивидендная доходность за последние 5 лет: 0.00%
История дивидендной доходности компании Gracell Biotechnologies Inc. (GRCL) с 2026 по 2026
Дивидендная доходность на конец каждого года (TTM)
Год Дивидендная доходность Изменить
Недостаточно данных для указанных дат.
Дивидендная доходность (TTM) аналогичных компаний или конкурентов
Компания Дивидендная доходность Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH